Cullinan Therapeutics, Inc. Common Stock CGEM
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:59:53.571Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:13:58.879777096Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:59:17.461876+00:00
Cullinan Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 9.60 | 270.6% | 25.6% | |||
| 30Δ | 10.26 | 249.3% | 21.2% | |||
| 35Δ | 10.85 | 218.9% | 16.8% | |||
| 40Δ | ||||||
| 45Δ | 14.26 | 333.8% | 35.4% | 12.21 | 297.5% | 16.5% |
| 50Δ | 13.52 | 348.6% | 31.7% | 12.60 | 260.7% | 13.1% |
| 55Δ | 12.74 | 359.9% | 27.8% | 13.00 | 223.9% | 9.7% |
| 60Δ | 11.84 | 350.8% | 22.3% | 13.29 | 205.3% | 7.9% |
| 65Δ | 10.91 | 294.0% | 14.4% | 13.58 | 186.9% | 6.2% |
| 70Δ | 10.36 | 251.4% | 9.9% | 13.87 | 168.5% | 4.5% |
| 75Δ | ||||||
| 80Δ | 18.01 | 266.3% | 3.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.60
- IV
- 270.6%
- B/E move
- 25.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.26
- IV
- 249.3%
- B/E move
- 21.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.85
- IV
- 218.9%
- B/E move
- 16.8%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 14.26
- IV
- 333.8%
- B/E move
- 35.4%
- Pseudo strike
- 12.21
- IV
- 297.5%
- B/E move
- 16.5%
50Δ
- Pseudo strike
- 13.52
- IV
- 348.6%
- B/E move
- 31.7%
- Pseudo strike
- 12.60
- IV
- 260.7%
- B/E move
- 13.1%
55Δ
- Pseudo strike
- 12.74
- IV
- 359.9%
- B/E move
- 27.8%
- Pseudo strike
- 13.00
- IV
- 223.9%
- B/E move
- 9.7%
60Δ
- Pseudo strike
- 11.84
- IV
- 350.8%
- B/E move
- 22.3%
- Pseudo strike
- 13.29
- IV
- 205.3%
- B/E move
- 7.9%
65Δ
- Pseudo strike
- 10.91
- IV
- 294.0%
- B/E move
- 14.4%
- Pseudo strike
- 13.58
- IV
- 186.9%
- B/E move
- 6.2%
70Δ
- Pseudo strike
- 10.36
- IV
- 251.4%
- B/E move
- 9.9%
- Pseudo strike
- 13.87
- IV
- 168.5%
- B/E move
- 4.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.01
- IV
- 266.3%
- B/E move
- 3.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 132.33% | |
| 130.49% | |
| 125.95% | |
| 130.89% | |
| 130.31% | |
| 137.63% | |
| 125.91% | |
| 137.84% | |
| 134.52% | |
| 129.05% |
Biotechnology
CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in…
More →CING
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders.…
More →CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.…
More →CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
More →CMPX
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The…
More →